Axumin [18F]-fluciclovine regulatory update

FDA approved an NDA from Blue Earth for Axumin [18F]-fluciclovine as a diagnostic PET imaging agent in men with suspected prostate cancer recurrence based on elevated levels of prostate-specific anti...